Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting

Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin and Markus Schwaiger
Journal of Nuclear Medicine June 1999, 40 (6) 1061-1071;
Roland Haubner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Wester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ute Reuning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reingard Senekowitsch-Schmidtke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beate Diefenbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Horst Kessler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Stöcklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Schwaiger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 40, Issue 6
June 1, 1999
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin, Markus Schwaiger
Journal of Nuclear Medicine Jun 1999, 40 (6) 1061-1071;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin, Markus Schwaiger
Journal of Nuclear Medicine Jun 1999, 40 (6) 1061-1071;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Complementary, Selective PET Imaging of Integrin Subtypes {alpha}5{beta}1 and {alpha}v{beta}3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin
  • 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study
  • Effects of Photoacoustic Imaging and Photothermal Ablation Therapy Mediated by Targeted Hollow Gold Nanospheres in an Orthotopic Mouse Xenograft Model of Glioma
  • Fluorescence Reflectance Imaging of Macrophage-Rich Atherosclerotic Plaques Using an {alpha}v{beta}3 Integrin-Targeted Fluorochrome
  • Radionuclide Imaging: A Molecular Key to the Atherosclerotic Plaque
  • Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice
  • Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography
  • Correlative Imaging of Hypoxia and Angiogenesis in Oncology
  • Integrin {alpha}V{beta}3 Binds to the RGD Motif of Glycoprotein B of Kaposi's Sarcoma-Associated Herpesvirus and Functions as an RGD-Dependent Entry Receptor
  • Noninvasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a 64Cu-Labeled RGD Peptide
  • Favorable Biokinetic and Tumor-Targeting Properties of 99mTc-Labeled Glucosamino RGD and Effect of Paclitaxel Therapy
  • How molecular imaging is speeding up antiangiogenic drug development
  • In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3
  • Positron Emission Tomography As an Imaging Biomarker
  • PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging {alpha}v{beta}3 Expression
  • Quantitative PET Imaging of Tumor Integrin {alpha}v{beta}3 Expression with 18F-FRGD2
  • Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size?
  • Targeting Tumor Angiogenesis: Comparison of Peptide and Polymer-Peptide Conjugates
  • Radiolabeled RGD Uptake and {alpha}v Integrin Expression Is Enhanced in Ischemic Murine Hindlimbs
  • Induction of Apoptosis with Hybrids of Arg-Gly-Asp Molecules and Peptides and Antimitotic Effects of Hybrids of Cytostatic Drugs and Peptides
  • Radiolabeled RGD Peptides Move Beyond Cancer: PET Imaging of Delayed-Type Hypersensitivity Reaction
  • Detection of Injury-Induced Vascular Remodeling by Targeting Activated {alpha}v{beta}3 Integrin In Vivo
  • Oncological molecular imaging: nuclear medicine techniques
  • Signaling through JAM-1 and {alpha}v{beta}3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and {alpha}v{beta}3 complex
  • Tumor Targeting with Radiolabeled {alpha}v{beta}3 Integrin Binding Peptides in a Nude Mouse Model
  • Arginine-Glycine-Aspartic Acid (RGD)-Peptide Binds to Both Tumor and Tumor-Endothelial Cells in Vivo
  • Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
  • Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
  • Noninvasive Imaging of {{alpha}}v{beta}3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography
  • Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics
  • Google Scholar

More in this TOC Section

  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
  • Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model
Show more Basic Science Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire